Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20050037.TNBC

— · C

7898581c-8472-567c-a354-202198e4e8e3

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • HEDGEHOG_SIGNALING+0.540
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
  • APICAL_SURFACE+0.480
  • MYOGENESIS+0.420
  • COAGULATION+0.400
  • WNT_BETA_CATENIN_SIGNALING+0.400
  • APICAL_JUNCTION+0.390
  • ANGIOGENESIS+0.380
  • UV_RESPONSE_DN+0.320
  • NOTCH_SIGNALING+0.300

Top 10 suppressed

  • E2F_TARGETS-0.600
  • MYC_TARGETS_V1-0.600
  • OXIDATIVE_PHOSPHORYLATION-0.500
  • MYC_TARGETS_V2-0.490
  • G2M_CHECKPOINT-0.480
  • MTORC1_SIGNALING-0.480
  • UNFOLDED_PROTEIN_RESPONSE-0.430
  • DNA_REPAIR-0.370
  • PROTEIN_SECRETION-0.360
  • INTERFERON_ALPHA_RESPONSE-0.270

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-HN-A2OB-01A-21R-A27Q-07
breast-umap@18
—A0.918
269d9a82b-5c37-45bd-a1cf-ffe1392e84fc
melanoma-umap@29
——0.910
3SRR33532754
breast-umap@18
—D0.907
4SRR8613732
breast-umap@18
—A0.906
5MNG128
mng-umap@100
——0.904
6TCGA-DK-A3IQ-01A-31R-A32Y-07
bladder-landscape@3
——0.902
7X9cad7a78.ea9b.47b0.9d06.e5e696031cc3
lung-landscapes@6
—cohortA10.898
857583139-d2d3-4b97-a616-aa96058d4682
melanoma-umap@29
——0.893
952162542-af1d-42ea-8f06-c6e042d9ac6c
colon-landscapes@1
——0.892
10TCGA-XF-AAMJ-01A-11R-A42T-07
bladder-landscape@3
——0.892

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HEDGEHOG_SIGNALING0.540Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.530Inavolisib— uncovered
APICAL_SURFACE0.480Temsirolimus— uncovered
MYOGENESIS0.420Inavolisib— uncovered
COAGULATION0.400Binimetinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.400Inavolisib— uncovered
APICAL_JUNCTION0.390Inavolisib— uncovered
ANGIOGENESIS0.380Remibrutinib— uncovered
UV_RESPONSE_DN0.320Inavolisib— uncovered
NOTCH_SIGNALING0.300Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.270Inavolisib— uncovered
KRAS_SIGNALING_DN0.250Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.210Cobimetinib— uncovered
TGF_BETA_SIGNALING0.180Inavolisib— uncovered
KRAS_SIGNALING_UP0.170Inavolisib— uncovered
BILE_ACID_METABOLISM0.120Inavolisib— uncovered
COMPLEMENT0.120Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.120Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.090Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.080Inavolisib— uncovered